Johnson & Johnson (JNJ) shares fell 1.6% in premarket trading despite reporting strong Q4 and full-year 2025 results. The company posted Q4 revenue of $24.56 billion, up 9.1% year-over-year and above analysts’ estimate of $24.16 billion. Meanwhile, adjusted EPS grew 20.6% to $2.46, but slightly missed the expected mark of $2.49.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential